Memorial Sloan-Kettering
AACR Project GENIE Enables Analysis of Growing Actionability, Disparities in Precision Oncology
Premium
At the annual meeting, researchers demonstrated how the growing real-world database can be useful in answering myriad research questions.
In a study presented at AACR, immunotherapy responses across 20 cancer types were consistently higher for tumors with TMB of at least 16 somatic mutations per megabase.Â
Genome Sequencing Identifies Myeloma Precursor Disease With High Progression Risk
Investigators flagged a set of myeloma-defining genomic events that marked precursor conditions that were prone to morph into multiple myeloma.
Researchers are increasingly arguing that the tissue-agnostic approval was too broad, and that tumor mutational burden is only a biomarker of response to immunotherapy in a handful of cancer types.
Precision Oncology Giant Jose Baselga Dies at 61
Baselga, who was instrumental in the development of several precision oncology drugs, died of the rare, neurologic Creutzfeldt-Jakob disease.